A 65-year-old man who recently had a myocardial infarction has elevated LDL cholesterol despite lifestyle changes. Which statin regimen would be most appropriate according to guidelines?

A 65-year-old man who recently had a myocardial infarction has elevated LDL cholesterol despite lifestyle changes. Which statin regimen would be most appropriate according to guidelines?

• A. Atorvastatin 80mg once daily
• B. Simvastatin 40mg once daily
• C. Rosuvastatin 20mg once daily
• D. Pravastatin 40mg once daily

Answer: (A)

After a myocardial infarction, the goal is strong secondary prevention with high‑intensity statin therapy to reduce recurrent events by lowering LDL by roughly 50% or more. The regimen with atorvastatin 80 mg once daily is a classic high‑intensity option that has robust evidence in post‑MI patients showing improved outcomes. This dose of atorvastatin is among the most potent standard regimens and is widely supported by guidelines for secondary prevention. Other choices listed are either less potent or carry more limitations in this particular context (pravastatin at 40 mg tends to produce smaller LDL reductions; simvastatin 40 mg is less favored now due to safety concerns and interactions; rosuvastatin 20 mg is also high‑intensity and would be acceptable, but the question's best single pick reflects the strongest, most well‑supported option in post‑MI care). So, starting with atorvastatin 80 mg daily aligns with the aim of achieving substantial LDL reduction and better long‑term outcomes after MI.

After a myocardial infarction, the goal is strong secondary prevention with high‑intensity statin therapy to reduce recurrent events by lowering LDL by roughly 50% or more. The regimen with atorvastatin 80 mg once daily is a classic high‑intensity option that has robust evidence in post‑MI patients showing improved outcomes.

This dose of atorvastatin is among the most potent standard regimens and is widely supported by guidelines for secondary prevention. Other choices listed are either less potent or carry more limitations in this particular context (pravastatin at 40 mg tends to produce smaller LDL reductions; simvastatin 40 mg is less favored now due to safety concerns and interactions; rosuvastatin 20 mg is also high‑intensity and would be acceptable, but the question's best single pick reflects the strongest, most well‑supported option in post‑MI care).

So, starting with atorvastatin 80 mg daily aligns with the aim of achieving substantial LDL reduction and better long‑term outcomes after MI.